Arshad Khanani, MD
Ophthalmology · Reno, NVNPI 1295929511
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,478,773 of the $2,012,970 with a category attached, or 73.5%. It is spread thinly across 49 manufacturers, the largest accounting for just 13.7%. Among ophthalmology clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,331 payments — averaging $1512.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- F. Hoffmann-la Roche AG$275K
- AbbVie$236K
- Genentech USA, Inc.$221K
- Astellas Pharma US Inc$203K
- Ocular Therapeutix, Inc.$201K
- Genentech, Inc.$194K
- plus $683K from 43 others
Across 2,655 payments — averaging $16,566 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$27M
- Ocular Therapeutix, Inc.$7.4M
- Novartis$3.8M
- Roche TCRC, Inc.$2.2M
- Kyowa Kirin, Inc.$1.2M
- Eyepoint US, Inc.$841K
- plus $1.6M from 10 others
What the payments were for
- Consulting fees$1,478,77373%
- Speaking & faculty fees$371,61418%
- Travel & lodging$134,6337%
- Food & beverage$27,2741%
- Education$6570%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Izervay$269,601
- Lucentis$159,142
- BEOVU$149,328
- VABYSMO$146,694
- SUSVIMO$96,233
- OZURDEX$75,758
- BLZ_BEOVU_OPHTHALMOLOGY$46,638
- Jetrea$31,656
- EYLEA$30,440
- Non-Covered Product$24,884
- DUREZOL$17,300
- Constellation$11,972
- RTH258A_BEOVU_OPHTHALMOLOGY$11,266
- PAVBLU$10,500
- XIPERE$9,775
- Syfovre$8,791
- EVA Ophthalmic Surgical System$7,125
- BUPARLISIB$5,247
- PURIFIED CORTROPHIN GEL$4,100
- EYP-1901$4,000
How this compares
$2,012,970 in reported general payments places this provider in the 95th percentile of 121 ophthalmology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 155 | $6,647 |
| Difluprednate | 25 | $4,391 |
| Brimonidine Tartrate | 17 | $1,684 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 45 | $718 |
| Timolol Maleate | 35 | $271 |
| MoxifloxacinMoxifloxacin Hcl | 14 | $250 |
| Latanoprost | 18 | $195 |
| Ciprofloxacin Hcl | 11 | $144 |
| ErythromycinErythromycin Base | 11 | $104 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Reno
- Steve ChangReno$75K
- Matthew MillsReno$15K
- Elena GeraymovychReno$14K
- Jamison EngleReno$6K
- Kevin GamettReno$6K
- Caleb MorrisReno$4K
- William DurantReno$4K
- Hardeep DhindsaReno$3K
- Peter FreemanReno$3K
- Xintong LiReno$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.